跳转至内容

Dear Customer:

The current international situation is complex and volatile, and uncertain tariff policies may potentially impact our product prices. Given these uncertainties, we value your understanding regarding order-related matters.

If you decide to place an order during this period, we reserve the right to adjust the price based on the evolving situation. We understand that market changes may cause inconvenience. We will negotiate with you if there’s a significant price fluctuation due to tariff policy changes before the order’s actual delivery, and in such cases we may adjust or cancel the order as necessary.

Merck
CN
所有图片(1)

主要文件

查看所有文档

V3640

Sigma-Aldrich

Valpromide

≥97% (NMR)

别名:

2-Propylvaleramide, 2-propyl-pentanamide, Depamid, Depamide, Di-n-propylacetamide, Dipropylacetamide

登录查看公司和协议定价

选择尺寸

1 KIT
¥4,429.37

¥4,429.37

预计发货时间2025年6月05日详情

购买套餐
获取大包装报价
所有图片(1)

选择尺寸

变更视图
1 KIT
¥4,429.37

About This Item

经验公式（希尔记法）:
C8H17NO
CAS号:
2430-27-5
分子量:
143.23
MDL编号:
MFCD00051534
UNSPSC代码:
12352200
PubChem化学物质编号:
329829044
NACRES:
NA.77

¥4,429.37

预计发货时间2025年6月05日详情

购买套餐
获取大包装报价

方案

≥97% (NMR)

表单

powder

颜色

white to off-white

溶解性

DMSO: >10 mg/mL

创始人

Sanofi Aventis

储存温度

room temp

SMILES字符串

CCCC(CCC)C(N)=O

InChI

1S/C8H17NO/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H2,9,10)

InChI key

OMOMUFTZPTXCHP-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

比较类似商品

查看完整比较结果

显示差异

1 of 4

此商品
917796918881918075
NanoFabTx™ PEGylated nanoparticle formulation screening kit

915408

NanoFabTx™ PEGylated nanoparticle formulation screening kit

NanoFabTx™ PEG-PLGA drug formulation screening kit for synthesis of PEGylated nanoparticles

917796

NanoFabTx™ PEG-PLGA drug formulation screening kit

NanoFabTx™ PEG-PCL drug formulation screening kit for synthesis of PEGylated nanoparticles

918881

NanoFabTx™ PEG-PCL drug formulation screening kit

NanoFabTx™ PLA-nano for synthesis of 100 and 200 nm particles

918075

NanoFabTx™ PLA-nano

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

2-8°C

description

Kit components :
PEGPLGA-50L (912808-500mg)
PEGPLGA-75L (913049-500mg)
PEGPLA-L (913308-500mg)
PEGPCL-H (912549-500mg)
Stabilizer - P (913448-10g)

description

Drug loading screening kit, for synthesis of PEGylated PLGA nanoparticles, Kit components :
PEGPLGA-50L(912808-500mg)
PEGPLGA-75L(913049-500mg)
PEGPLGA-50H (915955-500mg)
PEGPLGA-75H (915718-500mg)
Stabilizer-Nano (907766-5g)

description

Drug loading screening kit, for synthesis of PEGylated PCL nanoparticles, Kit components :
PEGPCL-L(915203-500mg)
PEGPCL-H(912549-500mg)
PEGPCL-UH (917788-500mg)
Stabilizer-Nano (907766-5g)

description

-

application(s)

advanced drug delivery

application(s)

advanced drug delivery

application(s)

advanced drug delivery

application(s)

advanced drug delivery

应用

Valpromide has been used to pretreat NIH/3T3 cells to test its effect on cytomegalovirus (CMV) viral replication.[1] It has also been used to test its antiviral functionality in herpes simplex virus type 1 (HSV-1) infected human oligodendroglioma (HOG) cells.[2] It may be used to test its effect on apoptosis induction in astrocytes.[3]

生化/生理作用

Valpromide (VPD) is a derivative of valproic acid (VPA) and is used as an antiepileptic drug.
Valpromide (VPD) is a derivative of valproic acid (VPA) and is used as an antiepileptic drug. It is hydrolyzed quickly to VPA in vivo, but has intrinsic anticonvulsant activity.
Valpromide possesses antipsychotic property. It lacks the toxic and teratogenic effects of valproic acid.[2] It also lacks the histone deacetylase (HDAC) inhibitory activity of valproic acid.[2]

特点和优势

This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

象形图

Exclamation mark
GHS07

警示用语：

Warning

危险声明

H302

危险分类

Acute Tox. 4 Oral

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

    • 历史批次信息供参考:

    分析证书(COA)

    Lot/Batch Number
    0000230384
    0000230385
    0000230385
    0000230384
    0000165455

    没有发现合适的版本？

    如果您需要特殊版本，可通过批号或批次号查找具体证书。

    搜索COA

    已有该产品？

    在文件库中查找您最近购买产品的文档。

    访问文档库

    Valproic acid induces apoptosis in differentiating hippocampal neurons by the release of tumor necrosis factor-alpha from activated astrocytes
    Wang C, et al.
    Neuroscience Letters, 497(2), 122-127 (2011)
    Cheng-Wei Li et al.
    PloS one, 13(8), e0202537-e0202537 (2018-08-23)
    Epstein-Barr virus (EBV), also known as human herpesvirus 4, is prevalent in all human populations. EBV mainly infects human B lymphocytes and epithelial cells, and is therefore associated with their various malignancies. To unravel the cellular mechanisms during the infection
    Karine Cambon et al.
    Molecular therapy. Methods & clinical development, 5, 259-276 (2017-06-13)
    Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder resulting from a polyglutamine expansion in the huntingtin (HTT) protein. There is currently no cure for this disease, but recent studies suggest that RNAi to downregulate the expression of both normal
    J A Shimshoni et al.
    Molecular pharmacology, 71(3), 884-892 (2006-12-15)
    Valproic acid (VPA) is an effective antiepileptic drug with an additional activity for the treatment of bipolar disorder. It has been assumed that both activities arise from a common target. At the molecular level, VPA targets a number of distinct
    Joseph R Calabrese et al.
    Bipolar disorders, 9(6), 628-635 (2007-09-12)
    Agomelatine has been shown to be safe and efficient in the treatment of major depressive disorder at 25 mg daily. The aim of this study was to gather preliminary data regarding the antidepressant efficacy of agomelatine in patients with bipolar
    查看所有相关文献

    我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

    联系客户支持